Sandoz edges closer to European market with Humira and Remicade biosimilars

31 May 2017

Sandoz, a division of Swiss pharma giant Novartis (NOVN: VX), has had its proposed adalimumab and infliximab biosimilars accepted for regulatory review by the European Medicines Agency (EMA).

The company is seeking approval for these biosimilars for use in all indications of their respective reference medicines, with the adalimumab product a copy of Humira from US drugmaker AbbVie (NYSE: ABBV), and infliximab referencing Remicade from Janssen, the pharma unit of healthcare giant Johnson & Johnson (NYSE: JNJ). Both are used to treat immunological diseases.

Comprehensive data packages demonstrate each biosimilar matches its respective reference medicine in terms of quality, efficacy and safety, Sandoz says.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK